Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Receivables (2016 - 2025)

IGC Pharma (IGC) has disclosed Receivables for 15 consecutive years, with $711000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Receivables fell 2.47% to $711000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $711000.0, a 2.47% decrease, with the full-year FY2025 number at $714000.0, down 1.52% from a year prior.
  • Receivables was $711000.0 for Q3 2025 at IGC Pharma, down from $767000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.2 million in Q2 2023 to a low of $493000.0 in Q1 2022.
  • A 5-year average of $764947.4 and a median of $725000.0 in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: surged 134.73% in 2023, then crashed 39.29% in 2024.
  • IGC Pharma's Receivables stood at $546000.0 in 2021, then skyrocketed by 83.52% to $1.0 million in 2022, then rose by 3.59% to $1.0 million in 2023, then decreased by 29.87% to $728000.0 in 2024, then fell by 2.34% to $711000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Receivables are $711000.0 (Q3 2025), $767000.0 (Q2 2025), and $714000.0 (Q1 2025).